sh-Polypeptide-4 for Hair Regrowth - Quick Reference Sheet

sh-Polypeptide-4 for Hair Regrowth

Created on 08/24/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A laboratory-made copy of a natural human signalling protein, sold in scalp serums. The biology behind it concerns hair colour more than hair thickness, and no study has tested the ingredient on its own. The protein is large enough that intact skin should block it, and nearly all supporting material comes from the companies selling it. (Full Review)

Protocol

Conventional approach
1-2 mL twice daily
Multi-factor serum on a dry scalp for at least two hair cycles (6-12 months). No validated protocol for the single agent.
Procedural approach
3-6 sessions, 2-6 weeks apart
Serum applied after microneedling at 0.5-1.5 mm or fractional laser. Neither route is the default.
Baseline biomarkers
Corrected first
Ferritin, vitamin D and thyroid function in most protocols, since deficiency otherwise masks any topical effect.
Time to effect
Time to effect
None established
No effect demonstrated, so no time course exists; growth-factor trials showed density changes at 3-6 months, full assessment at 12 months.
Duration
Indefinite
Any effect would depend on continuous receptor stimulation, so use behaves like the other topicals for pattern hair loss.
Post-discontinuation shedding
3-4 months
Any hair maintained in the growth phase by continued signalling would be expected to shed within this window after stopping.

Benefits

Contraindications
  • Systemic or cutaneous mastocytosis of any subtype, or baseline serum tryptase above 20 ng/mL
  • Documented KIT D816V mutation, or current or prior gastrointestinal stromal tumour
  • Personal history of melanoma, or dysplastic naevus syndrome with five or more atypical moles on the scalp or neck
  • Prior anaphylaxis or chronic spontaneous urticaria requiring more than standard-dose antihistamines
  • Active scalp infection, erosive scalp dermatitis, or scarring alopecia in the active inflammatory phase
  • Pregnancy and lactation
Key Interactions
  • KIT-inhibiting drugs (imatinib, sunitinib, ripretinib)
  • Systemic and potent topical corticosteroids (prednisone, dexamethasone, clobetasol)
  • Oral antihistamines (cetirizine, fexofenadine)
  • Topical retinoids (tretinoin, adapalene), salicylic acid and alcohol-based vehicles
  • Microneedling, fractional laser and mesotherapy
  • Platelet-rich plasma (PRP) and exosome preparations
  • Copper peptide (GHK-Cu) and other cosmetic peptide actives
  • Topical minoxidil

Risk & Side Effects

  • High:
  • Medium: Mast-cell activation and urticarial skin reactions; persistent skin hyperpigmentation at application sites
  • Low: Application-site irritation and contact sensitisation; forgone benefit from substituting for established therapy
  • Speculative: Proliferative signalling in pigment and mast cells; immune response against the body's own stem cell factor

Monitoring

Marker Target Why
Total hair density (1 cm² target area) No established target; usual trial threshold is a gain of 10 or more hairs/cm² from baseline The only direct measure of whether anything is working
Terminal-to-vellus hair ratio (1 cm² target area) At or above 4:1 Distinguishes recoverable thinning from follicles already lost
Ferritin 70-100 ng/mL (women); 100-150 ng/mL (men) Iron stores set growth-phase length
25-hydroxyvitamin D 40-60 ng/mL Vitamin D receptor activity is required for follicle cycling
TSH 0.5-2.0 mIU/L Thyroid dysfunction causes diffuse shedding that mimics treatment failure
Serum zinc 90-120 µg/dL Zinc deficiency shortens the growth phase and thins the shaft
Serum total tryptase Below 8 ng/mL Flags the expanded mast-cell population most likely to react to a mast-cell growth signal

Cadence: Baseline, then 3, 6 and 12 months; scalp photographs every 4 weeks during the first 3 months; deficiency panel repeated at 6 months if abnormal at baseline and annually thereafter.

Qualitative Assessment

  • Shedding volume on the pillow and in the shower drain, counted the same way each week
  • Whether the scalp shows through under overhead lighting in the standardised photographs
  • Perceived shaft stiffness and body, which shifts before hair count does
  • Scalp comfort: itch, tightness, flushing or warmth after application
  • Any new or darkening patches of scalp skin, examined monthly